E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedMachine draft
Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial.
Rowe, P C, Calkins, H, DeBusk, K et al. · JAMA · 2001 · DOI
Quick Summary
Many people with ME/CFS experience a drop in blood pressure when standing up (called neurally mediated hypotension), which may contribute to symptoms like dizziness and fatigue. This study tested whether a medication called fludrocortisone could help reduce ME/CFS symptoms in 100 patients with this blood pressure problem. After 9 weeks of treatment, the medication did not work better than placebo, suggesting it may not be an effective standalone treatment for this group.
Why It Matters
Orthostatic intolerance and blood pressure dysregulation are common, disabling features of ME/CFS, and identifying effective treatments could meaningfully improve quality of life. This rigorous trial provides evidence that fludrocortisone monotherapy is ineffective, guiding clinical practice and directing future research toward combination approaches or alternative interventions for orthostatic symptoms in ME/CFS.
Observed Findings
- Only 14% of fludrocortisone-treated subjects achieved ≥15-point improvement on the global wellness scale vs. 10% in placebo (P=.76, not statistically significant).
- No significant differences were observed between treatment groups on secondary symptom scores.
- There were no differences in the proportion with normal follow-up tilt-table test results between fludrocortisone and placebo groups.
- 71% of participants had ME/CFS for at least 3 years at baseline, suggesting a chronic, established disease population.
Inferred Conclusions
- Fludrocortisone acetate as monotherapy is not more effective than placebo for improving symptoms in adults with ME/CFS and neurally mediated hypotension.
- Other medications or combination therapeutic approaches may be necessary to effectively treat orthostatic intolerance in this population.
- Neurally mediated hypotension may contribute to ME/CFS symptoms, but addressing it alone with fludrocortisone is insufficient for symptomatic improvement.
Remaining Questions
- Would combination pharmacological therapy (e.g., fludrocortisone plus beta-blockers or other agents) be more effective than monotherapy?
- Are there patient subgroups or characteristics that predict better response to fludrocortisone or other orthostatic treatments?
What This Study Does Not Prove
This study does not prove that neurally mediated hypotension is unrelated to ME/CFS symptoms—only that fludrocortisone monotherapy does not ameliorate them. The failure to show benefit does not exclude the possibility that other medications, combination therapies, or dose adjustments might be effective. Lack of symptom improvement also does not exclude NMH as a pathophysiological contributor to the condition.
Tags
Symptom:Orthostatic IntoleranceFatigue
Method Flag:PEM Not DefinedSmall Sample
Metadata
- DOI
- 10.1001/jama.285.1.52
- PMID
- 11150109
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →